Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4212-4223

  Stewart, Grant D ^a,b   O'Mahony, Fiach C ^a,b   Laird, Alexander ^a,b,c   Eory, Lel ^c   Lubbock, Alexander L R ^c   Mackay, Alan ^d   Nanda, Jyoti ^a,b   O'Donnell, Marie ^a,b   Mullen, Peter ^e   McNeill, S Alan ^a,b   Riddick, Antony C P ^a,b   Berney, Daniel ^f   Bex, Axel ^g   Aitchison, Michael ^b,h   Overton, Ian M ^c   Harrison, David J ^b,e   Powles, Thomas ^f,h  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC)   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF ST ANDREWS   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SUNITINIB; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; INDOLE DERIVATIVE; NUCLEAR PROTEIN; PBRM1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; TRANSCRIPTION FACTOR; VHL PROTEIN, HUMAN;

ADULT; ARTICLE; BAP1 GENE; CAIX GENE; CANCER GRADING; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE EXACERBATION; DNA EXTRACTION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC STABILITY; GENOTYPE; HIF1A GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; KIDNEY CANCER; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MTOR GENE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PBRM1 GENE; PDGFA GENE; PDGFB GENE; PDGFRB GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SETD2 GENE; TUMOR GENE; VCAM1 GENE; VEGFA GENE; VEGFR2 GENE; AGED; ANOXIA; CARCINOMA, RENAL CELL; CLUSTER ANALYSIS; DRUG DESIGN; GENE EXPRESSION PROFILING; GENETICS; KIDNEY NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PILOT STUDY;

AGED; ANOXIA; ANTINEOPLASTIC AGENTS; BIOMARKERS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG DESIGN; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEPHRECTOMY; NUCLEAR PROTEINS; PILOT PROJECTS; PROTEIN ARRAY ANALYSIS; PROTEIN KINASE INHIBITORS; PYRROLES; RNA, MESSENGER; TRANSCRIPTION FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84942880543     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0207     Document Type: Article

References (23)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
2. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014;4:61-8.
3. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
4. Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, et al. The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res 2013;19:6924-34.
5. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014;8:1095-111.
6. Huang D, Ding Y, Li Y, Luo W-M, Zhang Z-F, Snider J, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010;70:1053-62.
7. O'Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, et al. The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers. J Vis Exp JoVE 2013; pii:50221.
8. Gerth-Kahlert C, Williamson K, Ansari M, Rainger JK, Hingst V, Zimmermann T, et al. Clinical and mutation analysis of 51 probands with anophthalmia and/or severe microphthalmia from a single center. Mol Genet Genomic Med 2013;1:15-31.
9. Turnbull AK, Kitchen RR, Larionov AA, Renshaw L, Dixon JM, Sims AH. Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis. BMC 2012;5:35.
10. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, TanDSP, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010;121:575-89.
11. Turnbull AK, Arthur L, Renshaw L, Larionov AA, Kay C, Dunbier AK, et al. Accurate prediction and validation of response to endocrine therapy in breast cancer. J Clin Oncol. 2015 Jun 1. [Epub ahead of print]; In press.
12. Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, et al. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol 2014;66:956-63.
13. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostat Oxf Engl 2007;8:118-27.
14. Neeley ES, Kornblau SM, Coombes KR, Baggerly KA. Variable slope normalization of reverse phase protein arrays. Bioinformatics 2009;25: 1384-9.
15. Natrajan R, Lambros MB, Rodríguez-Pinilla SM, Moreno-Bueno G, Tan DSP, Marchió C, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009;15:2711-22.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 1995;57:289-300.
17. Maier T, Güell M, Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett 2009;583:3966-73.
18. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012;12:487-93.
19. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
20. Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 2014;32:1968-76.
21. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013;14:159-67.
22. Stewart GD, Harrison DJ, Swanton C, Lewis R, Bliss J, Larkin J, et al. Multidisciplinary urological engagement in translational renal cancer research. BJU Int 2014;114:474-5.
23. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.